Publications by authors named "Laura Concas"

Claim this Profile
I
Incidence of type 1 diabetes in Sardinian children aged 0-14 years has almost doubled in the last twenty years. On top of the world.
Carlo Ripoli, Maria R Ricciardi, Maria R Angelo, Gianfranco Meloni, Antonello Pippia, Laura Concas

Diabetes Res Clin Pract· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large Left Atrial Thrombus in a Patient With Severe Mitral Stenosis and Atrial Fibrillation Despite Anticoagulant Therapy: A Case Report.
Silvio Nocco, Laura Concas, Marco Fei

Cureus· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Sara Pusceddu, Claudio Vernieri, Massimo Di Maio, Riccardo Marconcini, Francesca Spada, Laura Concas

Gastroenterology· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of succinate dehydrogenase subunit B (SDHB) as a prognostic factor in advanced ileal well-differentiated neuroendocrine tumors.
Massimo Milione, Patrick Maisonneuve, Alessio Pellegrinelli, Sara Pusceddu, Giovanni Centonze, Laura Concas

Endocrine· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors.
Sara Pusceddu, Natalie Prinzi, Giuseppe Lo Russo, Daniela Femia, Massimo Milione, Laura Concas

Future Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors.
Rossana Berardi, Mariangela Torniai, Sara Pusceddu, Francesca Spada, Toni Ibrahim, Laura Concas

Cancer Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories.
Massimo Milione, Patrick Maisonneuve, Francesca Spada, Alessio Pellegrinelli, Paola Spaggiari, Laura Concas

Neuroendocrinology· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus treatment for neuroendocrine tumors: latest results and clinical potential.
Sara Pusceddu, Elena Verzoni, Natialie Prinzi, Alessia Mennitto, Daniela Femia, Laura Concas

Ther Adv Med Oncol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Update on medical treatment of small intestinal neuroendocrine tumors.
Sara Pusceddu, Daniela Femia, Giuseppe Lo Russo, Silvia Ortolani, Massimo Milione, Laura Concas

Expert Rev Anticancer Ther· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities? A Case Report with a 6-Year Follow-Up.
Claudio Vernieri, Daniela Femia, Sara Pusceddu, Carlo Capella, Juan Rosai, Laura Concas

Case Rep Oncol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies.
Sara Pusceddu, Filippo De Braud, Giuseppe Lo Russo, Laura Concas, Daniela Femia

Oncotarget· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes.
Sara Pusceddu, Roberto Buzzoni, Claudio Vernieri, Laura Concas, Sara Marceglia

Future Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review.
Sara Pusceddu, Filippo De Braud, Fabrizio Festinese, Cristina Bregant, Alice Lorenzoni, Laura Concas

Future Oncol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left atrial myxoma with an extremely mobile thread-like offshoot.
Silvio Nocco, Laura Concas, Rinaldo Aste

J Echocardiogr· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Sara Pusceddu, Filippo de Braud, Laura Concas, Cristina Bregant, Livia Leuzzi

Tumori· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis